SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
Email Signup | RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

SafetyLit Journal Details

We are unable to provide photocopies of any the articles and reports abstracted in SafetyLit updates. Where possible, links have been provided to the publisher of the material and contact information for the corresponding author is listed. Please consider asking your library to subscribe to the journals from which these abstracts have been gathered.

To recommend a journal for this list please: Send SafetyLit an Email Message


Receptors and clinical investigation

Abbreviation: Receptors Clin. Investig.

Published by: Smart Science and Technology

Publisher Location: Houston, TX, USA

Journal Website: Unavailable


Range of citations in the SafetyLit database: 2016; 3(1) -- 2016; 3(1)

Publication Date Range: 2014 --

Title began with volume (issue): 1(1)

Number of articles from this journal included in the SafetyLit database: 1
(Download all articles from this journal in CSV format.)

pISSN = 2330-0558 | eISSN = 2330-0566
LCCN = 2013203360 | USNLM = 101624709 | OCLC = 852795929


Find a library that holds this journal: http://worldcat.org/issn/23300558

Journal Language(s): English


Aims and Scope (from publisher): Receptors and Clinical Investigation is an open access, peer-reviewed, online journal that encompasses all basic and translational aspects of receptors and associated signaling pathways in normal and pathological conditions. The study of receptors including tyrosine kinases,VEGF receptor, dopamine receptor, estrogen receptors, glucocorticoids receptors, thyroid hormone receptors, Calcium Sensing Receptor, G-protein coupled receptors and T-cell receptors has been of fundamental biological interest with implications for treating a wide range of ailments including cancer, diabetes and atherosclerosis. In addition to that, ligands, coregulators, modulators, and drugs acting on receptors have been deeply studied. Our understanding of such biology has led to the discovery and use of therapeutics, including small molecule inhibitors and humanized antibodies that have been approved for treatment of cancer and ocular disease. By considering past and current advances in the field, this journal is expected to bridge receptors and associated signaling pathways with clinical investigation.